Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000591699 | SCV000705979 | uncertain significance | not provided | 2017-01-27 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005027708 | SCV005650542 | uncertain significance | Alagille syndrome due to a NOTCH2 point mutation; Hajdu-Cheney syndrome | 2023-12-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005091568 | SCV005846742 | uncertain significance | Hajdu-Cheney syndrome | 2024-05-23 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with histidine, which is basic and polar, at codon 2035 of the NOTCH2 protein (p.Asn2035His). This variant is present in population databases (rs745697811, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with NOTCH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 500159). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on NOTCH2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |